Clinical Trials Logo

Clinical Trial Summary

Mitochondrial diseases caused by defects in oxidative phosphorylation (OXPHOS) due to heteroplasmic mitochondrial DNA (mtDNA) mutations are rare (frequency 1/5,000), but severe multi-system disorders. Clinical manifestations are highly variable, but predominantly affect energy demanding tissues, like brain and muscle. Myopathy is a common feature of mtDNA disorders, being present in more than 50% of the mtDNA mutation carriers, and seriously affects patients' general well-being and quality of life. Currently, no treatment is available for these patients, although the induction of muscle regeneration by exercise treatment has been shown to alleviate their myopathy. This implies that these patients can produce muscle fibres that perform better, most likely because the mutation load is lower. Mesoangioblasts (MABs) are myogenic precursors that have been recognized as a source for development of a systemic myogenic stem-cell therapy. Autologous MABs may be feasible for half of the mtDNA mutation carriers of 6 different mtDNA mutations, as their mtDNA mutation load in mesoangioblasts was (nearly) absent (<10%). However, there are many more mtDNA mutations in the 16.5kb mtDNA and the aim of this study is to determine the mtDNA mutation load in mesoangioblasts of other mtDNA mutation carriers and identify the patients or mutations for which this is a feasible approach.


Clinical Trial Description

Rationale: Mitochondrial diseases caused by defects in oxidative phosphorylation (OXPHOS) due to heteroplasmic mitochondrial DNA (mtDNA) mutations are rare (frequency 1/5,000), but severe multi-system disorders. Clinical manifestations are highly variable, but predominantly affect energy demanding tissues, like brain and muscle. Myopathy is a common feature of mtDNA disorders, being present in more than 50% of the mtDNA mutation carriers, and seriously affects patients' general well-being and quality of life. Currently, no treatment is available for these patients, although the induction of muscle regeneration by exercise treatment has been shown to alleviate their myopathy. This implies that these patients can produce muscle fibres that perform better, most likely because the mutation load is lower. Mesoangioblasts (MABs) are myogenic precursors that have been recognized as a source for development of a systemic myogenic stem-cell therapy, and allogeneic transplantation has been successfully applied to mice and dogs with Duchenne muscular dystrophy. A subsequent phase I/II clinical study in boys with DMD demonstrated that donor MABs treatment was relatively safe, but did not result in clinical improvement, which can partly be attributed to the required use of immunosuppressive agents. The use of autologous MABs would circumvent this and a previous study of our group demonstrated that this is feasible for half of the mtDNA mutation carriers of 6 different mtDNA mutations, as their mtDNA mutation load in mesoangioblasts was (nearly) absent (<10%). However, there are many more mtDNA mutations in the 16.5kb mtDNA and the aim of this study is to determine the mtDNA mutation load in mesoangioblasts of other mtDNA mutation carriers and identify the patients or mutations for which this is a feasible approach. Objective: The primary objectives of this project is to assess the mtDNA mutation load in mesoangioblasts of mtDNA mutation carriers and identify which patients display no/low (<10%) mtDNA mutation load in mesoangioblasts. Secondary objectives aim at determining the proliferation, myogenic differentiation and OXPHOS capacity of mesoangioblasts, their systemic inflammation status and assessment of the mtDNA mutation load in satellite cells. Study design: Mono-centre observation study. Study population: 30 adult carriers of a heteroplasmic mtDNA point-mutation or large-scale mtDNA deletion (>2kb). Intervention: From each participant, a 30mg skeletal muscle biopsy and a 20ml venous blood sample will be collected. Main study parameters/endpoints: Assess the mtDNA mutation load in skeletal muscle derived mesoangioblasts. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05199740
Study type Observational
Source Maastricht University
Contact Florence van Tienen, PhD
Phone 314332918
Email [email protected]
Status Not yet recruiting
Phase
Start date February 1, 2022
Completion date July 1, 2026

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04086329 - Validation of Oxygen Nanosensor in Mitochondrial Myopathy N/A
Completed NCT02909400 - The KHENERGY Study Phase 2
Active, not recruiting NCT04165239 - The KHENERGYZE Study Phase 2
Completed NCT02255422 - RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR Phase 2
Recruiting NCT05012358 - Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine
Recruiting NCT05162768 - Study to Evaluate the Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Nuclear DNA Mutations (nPMD) Phase 3
Completed NCT03888716 - A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease Phase 1
Recruiting NCT05063721 - MABs Therapy m.3243A>G Mutation Carriers Phase 1
Completed NCT03973203 - Niacin Supplementation in Healthy Controls and Mitochondrial Myopathy Patients N/A
Recruiting NCT05200702 - Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders N/A
Recruiting NCT03513835 - Diagnostic Screening Tests and Potential Biomarkers in Mitochondrial Myopathies
Completed NCT04538521 - NiaMIT Continuation With Early-stage Mitochondrial Myopathy Patients N/A
Recruiting NCT03432871 - Nicotinamide Riboside and Mitochondrial Biogenesis N/A
Completed NCT02375438 - Nutritional Assessment in Mitochondrial Cytopathy N/A
Recruiting NCT05199246 - Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders N/A
Completed NCT03728777 - Resveratrol Supplementation in Patients With Mitochondrial Myopathies and Skeletal Muscle Fatty Acid Oxidation Disorders N/A
Not yet recruiting NCT05346627 - Home Based Personalized Training and Video Consultation in Mitochondrial Myopathies: Study of Efficacy and Tolerance. N/A